vs

Side-by-side financial comparison of Enact Holdings, Inc. (ACT) and REPLIGEN CORP (RGEN). Click either name above to swap in a different company.

Enact Holdings, Inc. is the larger business by last-quarter revenue ($312.7M vs $197.9M, roughly 1.6× REPLIGEN CORP). On growth, REPLIGEN CORP posted the faster year-over-year revenue change (13.6% vs 3.6%). Over the past eight quarters, REPLIGEN CORP's revenue compounded faster (14.4% CAGR vs 3.6%).

Enact Holdings, Inc. is a leading U.S.-based private mortgage insurance provider. It delivers risk mitigation solutions to residential mortgage lenders, banks, and credit unions, enabling borrowers with smaller down payments to access affordable home financing, and supports sustainable homeownership for diverse consumer groups across the United States.

Repligen Corporation is a global life sciences company devoted to the development and commercialization of innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs.2025 The company is based in Waltham, Massachusetts,2014 and was incorporated in Delaware in 1981. A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. As of 2025, Repligen employs over 1,900 employees globally and serves primarily biop...

ACT vs RGEN — Head-to-Head

Bigger by revenue
ACT
ACT
1.6× larger
ACT
$312.7M
$197.9M
RGEN
Growing faster (revenue YoY)
RGEN
RGEN
+10.0% gap
RGEN
13.6%
3.6%
ACT
Faster 2-yr revenue CAGR
RGEN
RGEN
Annualised
RGEN
14.4%
3.6%
ACT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACT
ACT
RGEN
RGEN
Revenue
$312.7M
$197.9M
Net Profit
$13.3M
Gross Margin
52.5%
Operating Margin
71.3%
9.0%
Net Margin
6.7%
Revenue YoY
3.6%
13.6%
Net Profit YoY
143.9%
EPS (diluted)
$1.23
$0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACT
ACT
RGEN
RGEN
Q4 25
$312.7M
$197.9M
Q3 25
$311.5M
$188.8M
Q2 25
$304.9M
$182.4M
Q1 25
$306.8M
$169.2M
Q4 24
$301.8M
$174.1M
Q3 24
$309.6M
$154.9M
Q2 24
$298.8M
$154.1M
Q1 24
$291.6M
$151.3M
Net Profit
ACT
ACT
RGEN
RGEN
Q4 25
$13.3M
Q3 25
$14.9M
Q2 25
$14.9M
Q1 25
$5.8M
Q4 24
$-30.3M
Q3 24
$-654.0K
Q2 24
$3.3M
Q1 24
$2.1M
Gross Margin
ACT
ACT
RGEN
RGEN
Q4 25
52.5%
Q3 25
53.2%
Q2 25
50.0%
Q1 25
53.6%
Q4 24
26.1%
Q3 24
50.0%
Q2 24
49.8%
Q1 24
49.5%
Operating Margin
ACT
ACT
RGEN
RGEN
Q4 25
71.3%
9.0%
Q3 25
67.4%
8.9%
Q2 25
70.4%
7.6%
Q1 25
68.9%
3.9%
Q4 24
68.9%
-17.7%
Q3 24
74.1%
-5.1%
Q2 24
78.6%
1.0%
Q1 24
70.6%
1.3%
Net Margin
ACT
ACT
RGEN
RGEN
Q4 25
6.7%
Q3 25
7.9%
Q2 25
8.2%
Q1 25
3.4%
Q4 24
-17.4%
Q3 24
-0.4%
Q2 24
2.2%
Q1 24
1.4%
EPS (diluted)
ACT
ACT
RGEN
RGEN
Q4 25
$1.23
$0.24
Q3 25
$1.10
$0.26
Q2 25
$1.11
$0.26
Q1 25
$1.08
$0.10
Q4 24
$1.05
$-0.55
Q3 24
$1.15
$-0.01
Q2 24
$1.16
$0.06
Q1 24
$1.01
$0.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACT
ACT
RGEN
RGEN
Cash + ST InvestmentsLiquidity on hand
$582.5M
$767.6M
Total DebtLower is stronger
$744.5M
$542.2M
Stockholders' EquityBook value
$5.4B
$2.1B
Total Assets
$6.9B
$2.9B
Debt / EquityLower = less leverage
0.14×
0.26×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACT
ACT
RGEN
RGEN
Q4 25
$582.5M
$767.6M
Q3 25
$545.6M
$748.7M
Q2 25
$616.0M
$708.9M
Q1 25
$639.0M
$697.2M
Q4 24
$602.8M
$757.4M
Q3 24
$674.9M
$784.0M
Q2 24
$711.3M
$809.1M
Q1 24
$624.3M
$780.6M
Total Debt
ACT
ACT
RGEN
RGEN
Q4 25
$744.5M
$542.2M
Q3 25
$744.1M
$537.9M
Q2 25
$743.8M
Q1 25
$743.4M
Q4 24
$743.0M
$525.6M
Q3 24
$742.7M
Q2 24
$742.4M
Q1 24
$746.1M
Stockholders' Equity
ACT
ACT
RGEN
RGEN
Q4 25
$5.4B
$2.1B
Q3 25
$5.3B
$2.1B
Q2 25
$5.2B
$2.1B
Q1 25
$5.1B
$2.0B
Q4 24
$5.0B
$2.0B
Q3 24
$5.0B
$2.0B
Q2 24
$4.8B
$2.0B
Q1 24
$4.7B
$2.0B
Total Assets
ACT
ACT
RGEN
RGEN
Q4 25
$6.9B
$2.9B
Q3 25
$6.9B
$2.9B
Q2 25
$6.8B
$2.9B
Q1 25
$6.7B
$2.9B
Q4 24
$6.5B
$2.8B
Q3 24
$6.6B
$2.8B
Q2 24
$6.3B
$2.9B
Q1 24
$6.3B
$2.8B
Debt / Equity
ACT
ACT
RGEN
RGEN
Q4 25
0.14×
0.26×
Q3 25
0.14×
0.26×
Q2 25
0.14×
Q1 25
0.15×
Q4 24
0.15×
0.27×
Q3 24
0.15×
Q2 24
0.15×
Q1 24
0.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACT
ACT
RGEN
RGEN
Operating Cash FlowLast quarter
$724.5M
$25.7M
Free Cash FlowOCF − Capex
$17.6M
FCF MarginFCF / Revenue
8.9%
Capex IntensityCapex / Revenue
4.1%
Cash ConversionOCF / Net Profit
1.93×
TTM Free Cash FlowTrailing 4 quarters
$93.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACT
ACT
RGEN
RGEN
Q4 25
$724.5M
$25.7M
Q3 25
$192.0M
$48.1M
Q2 25
$119.5M
$28.6M
Q1 25
$226.7M
$15.0M
Q4 24
$686.3M
$39.2M
Q3 24
$188.1M
$49.3M
Q2 24
$144.7M
$42.2M
Q1 24
$187.3M
$44.7M
Free Cash Flow
ACT
ACT
RGEN
RGEN
Q4 25
$17.6M
Q3 25
$43.4M
Q2 25
$21.5M
Q1 25
$11.4M
Q4 24
$33.6M
Q3 24
$42.3M
Q2 24
$37.4M
Q1 24
$36.4M
FCF Margin
ACT
ACT
RGEN
RGEN
Q4 25
8.9%
Q3 25
23.0%
Q2 25
11.8%
Q1 25
6.8%
Q4 24
19.3%
Q3 24
27.3%
Q2 24
24.3%
Q1 24
24.0%
Capex Intensity
ACT
ACT
RGEN
RGEN
Q4 25
4.1%
Q3 25
2.5%
Q2 25
3.9%
Q1 25
2.1%
Q4 24
3.2%
Q3 24
4.5%
Q2 24
3.1%
Q1 24
5.5%
Cash Conversion
ACT
ACT
RGEN
RGEN
Q4 25
1.93×
Q3 25
3.23×
Q2 25
1.92×
Q1 25
2.57×
Q4 24
Q3 24
Q2 24
12.70×
Q1 24
21.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons